文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

二氯乙酸酯刺激丙酮酸脱氢酶复合体可能改善脓毒性心脏功能障碍

Pyruvate Dehydrogenase Complex Stimulation With Dichloroacetate May Improve Septic Cardiac Dysfunction.
PubMed 文献 · Shock · 2025-10-31
一句话结论小鼠脓毒症模型中,二氯乙酸酯(DCA)激活丙酮酸脱氢酶可改善早期心脏前负荷与每搏输出量、晚期心肌收缩力,但作者认为其治疗脓毒性心肌病的有效性仍需进一步研究。

本研究在小鼠盲肠结扎穿孔(CLP)脓毒症模型中探索二氯乙酸酯(DCA)对脓毒性心脏功能障碍的作用。CLP显著增加PDH E1α亚基磷酸化(PDH失活),DCA治疗使PDH E1α磷酸化降至基线水平而不影响总PDH E1α水平。CLP时给予DCA在CLP后12小时改善心脏前负荷和每搏输出量而不影响心肌收缩力,但在DCA给药后30小时心肌收缩力显著增加且不依赖心脏负荷条件。DCA改善心功能与生酮氨基酸、琥珀酸和棕榈酰肉碱等代谢中间产物生成减少的趋势相关,成像质谱显示CLP后衣康酸表达增加而被DCA减轻。作者结论认为,进一步研究必要以确定DCA是否为脓毒性心肌病的有效治疗药物。

要点

  • 在CLP小鼠模型中,CLP显著增加PDH E1α亚基磷酸化(PDH失活),DCA治疗使PDH E1α磷酸化降至基线水平且不影响总PDH E1α水平。
  • CLP时给予DCA在CLP后12小时改善心脏前负荷和每搏输出量,但不影响心肌收缩力。
  • 在DCA给药后30小时,心肌收缩力显著增加且不依赖心脏负荷条件。
  • DCA改善心功能与生酮氨基酸、琥珀酸和棕榈酰肉碱等代谢中间产物生成减少的趋势相关;成像质谱显示CLP后衣康酸表达增加而被DCA减轻。
  • 作者结论:脓毒症降低心脏组织PDH活性,DCA重平衡PDH活性改善CLP后心脏功能,但DCA是否为脓毒性心肌病的有效治疗药物仍需进一步研究。

适用人群与场景

  • 小鼠盲肠结扎穿孔(CLP)脓毒症模型
  • 早期脓毒症(CLP后12小时)和晚期脓毒症(DCA给药后30小时)

处置流程与药物剂量

  • 在CLP时给予小鼠二氯乙酸酯(DCA)以测试PDH激活对心脏性能和心肌代谢底物生成的影响;原文未写明DCA的剂量、给药途径和频次。

研究设计与关键结果

  • 研究类型:小鼠脓毒症模型实验;样本量、中心数原文未报告。
  • CLP显著增加PDH E1α亚基磷酸化(PDH失活),DCA治疗使PDH E1α磷酸化降至基线水平而不影响总PDH E1α水平。
  • CLP时给予DCA在CLP后12小时改善心脏前负荷和每搏输出量而不影响心肌收缩力。
  • 在DCA给药后30小时心肌收缩力显著增加且不依赖心脏负荷条件。
  • DCA改善心功能与生酮氨基酸、琥珀酸和棕榈酰肉碱等代谢中间产物生成减少的趋势相关。
  • 成像质谱显示CLP后衣康酸表达增加,DCA给药减轻该增加。

证据类型、等级与局限

  • 证据类型:小鼠脓毒症模型实验研究。
  • 局限:原文报告进一步研究必要以确定DCA是否为脓毒性心肌病的有效治疗药物。

对床旁实践的改变

  • 原文为小鼠CLP脓毒症模型实验,作者结论认为进一步研究必要以确定DCA是否为脓毒性心肌病的有效治疗药物,未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cardiomyopathy is a common complication of sepsis that contributes to increased morbidity and mortality. However, the molecular mechanisms underlying septic cardiomyopathy are poorly understood. Dichloroacetate (DCA) improves mitochondrial respiration and survival in a mouse model of sepsis by inhibiting pyruvate dehydrogenase kinase, which inactivates pyruvate dehydrogenase (PDH) through phosphorylation of its subunits. In this study, we explore the role of DCA in septic cardiac dysfunction using a murine sepsis model.

METHODS: Cecal ligation and puncture (CLP) was performed in mice to investigate molecular and echocardiographic response to sepsis. DCA was administered to test the effects of PDH activation on cardiac performance during early and late sepsis and myocardial metabolic substrate production. Matrix-assisted laser desorption/ionization imaging mass spectrometry was used to reveal spatial alterations in metabolism.

RESULTS: CLP significantly increased phosphorylation of the PDH E1α subunit (PDH inactivation), and DCA treatment reduced PDH E1α phosphorylation (PDH activation) to baseline without affecting total PDH E1α levels. Administration of DCA at the time of CLP improved cardiac preload and stroke volume without affecting cardiac contractility at 12 h after CLP. However, there was a significant increase in cardiac contractility at 30 h after DCA administration independent of cardiac loading conditions. This improved cardiac function after DCA administration was associated with a trend toward decreased production of metabolic intermediates such as ketogenic amino acids, succinate, and palmitoyl carnitine. Imaging mass spectrometry revealed an increase in itaconate expression upon CLP that was mitigated by DCA administration.

CONCLUSION: Our findings revealed that sepsis decreased PDH activity in cardiac tissue. Rebalancing PDH activity with DCA improved cardiac performance after CLP. While imaging mass spectrometry identified changes in itaconate concentration and enabled detection of tricarboxylic acid cycle metabolites, further investigation is necessary to determine whether DCA is an effective therapeutic agent for septic cardiomyopathy.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Smith LM, Lin YT, Mertens CS, et al. Pyruvate Dehydrogenase Complex Stimulation With Dichloroacetate May Improve Septic Cardiac Dysfunction. Shock. 2025. PMID: 41170803. doi:10.1097/SHK.0000000000002642

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。